Dra. Rocío García Carbonero

Nº total: 128

Publicaciones más destacadas:

1. R. Garcia-Carbonero, M. Hidalgo, L. Paz-Ares, J. Calzas, H. Gomez, JA. Guerra, R. Hitt, J. Hornedo, R. Colomer and H. Cortés-Funes: Patient selection in High-Dose Chemotherapy Trials: Relevance in High-Risk Breast Cancer. J Clin Oncol 15: 3178-3184, 1997.
2. R.Garcia-Carbonero, J.I.Mayordomo, M.V.Tornamira, M.Lopez-Brea, A.Rueda, V.Guillem, A.Arcediano, A.Yubero, F.Rivera, C.Gomez, A.Tres, J.L.Perez-Gracia, C.Lumbreras, H.Cortes-Funes and L.Paz-Ares. Granulocyte colony-stimulating factor (G-CSF) in the treatment of high-risk febrile neutropenia: Results of a multicenter randomized phase III trial. J Natl Cancer Inst 2001 Jan; 93(1): 31-38.
3. Rocio Garcia-Carbonero and Jeffrey G. Supko. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clinical Cancer Res 2002 Mar; 8(3):641-61.
4. R.Garcia-Carbonero, J.G. Supko, J. Manola, M.V. Seiden, D. Harmon, D.P. Ryan, M.T. Quigley, P. Merriam, J. Canniff, G. Goss, U. Matulonis, R.G. Maki, T. Lopez, T.A. Puchalski, M. A. Sancho, J. Gomez, C. Guzman, J. Jimeno, and G.D. Demetri. Phase II and pharmacokinetic study of Ecteinascidin-743 (ET-743) in patients with progressive sarcomas of soft tissues following failure of conventional chemotherapy. J Clin Oncol Apr 15;22(8):1480-90, 2004.
5. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent-Viñuelas M, Monleon A and Salazar R. Incidence, Patterns of Care and Prognostic Factors for Outcome of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010 Sep;21(9):1794-803.
6. J. Tabernero, R. Garcia-Carbonero, J. Cassidy, A. Sobrero, E. Van Cutsem, C.H. Köhne, S. Tejpar, O. Gladkov, I. Davidenko, R. Salazar, L. Vladimirova, S. Cheporov, O. Burdaeva, F. Rivera, L. Samuel, I. Bulavina, V. Potter, Y.L. Chang, N. A. Lokker, P. J. O'Dwyer. Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial. Clin Cancer Res 2013 May 1;19(9):2541-50.
7. Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncology 2013 Aug;14(9):e358-69.
8. Garcia-Carbonero R, Rivera F, Maurel J, Ayoub JP, Moore MJ, Cervantes A, Asmis TR, Schwartz JD, Nasroulah F, Ballal S, Tabernero J. An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer. Oncologist. 2014 Apr;19(4):350-1.
9. Purificacion Estevez-Garcia, Fernando Rivera, Sonia Molina-Pinelo, Marta Benavent, Javier Gómez, Maria Luisa Limón, Maria Dolores Pastor, Julia Martinez-Perez, Luis Paz-Ares, Amancio Carnero and Rocio Garcia-Carbonero*. Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer. Oncotarget 2015 Mar 20;6(8):6151-9.
10. Rodrigo Dienstmann, Amita Patnaik, Rocio Garcia-Carbonero, Andrés Cervantes, Marta Benavent, Susana Roselló, Bastiaan B. J. Tops, Rachel S. van der Post, Guillem Argiles, Niels J.Ø. Skartved, Ulla H. Hansen, Rikke Hald, Mikkel W. Pedersen, Michael Kragh, Ivan D. Horak, Stephan Braun, Eric van Cutsem, Anthony W. Tolcher, and Josep Tabernero. Safety and Activity of the First-in-class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discovery 2015 Jun;5(6):598-609.
11. Robert J. Mayer, Eric Van Cutsem, Alfredo Falcone, Takayuki Yoshino, Rocio Garcia-Carbonero, Nobuyuki Mizunuma, Kentaro Yamazaki, Yasuhiro Shimada, Josep Tabernero, Yoshito Komatsu, Alberto Sobrero, Eveline Boucher, Marc Peeters, Ben Tran, Heinz-Josef Lenz, Alberto Zaniboni, Howard Hochster, James M. Cleary, Hans Prenen, Fabio Benedetti, Hirokazu Mizuguchi, Lukas Makris, Masanobu Ito, Atsushi Ohtsu, on behalf of the RECOURSE Study Group. TAS-102 monotherapy for metastatic colorectal cancer refractory to standard therapies (RECOURSE): a multicenter, randomized, double-blind, phase 3 trial. New England Journal of Medicine 2015 May 14;372(20):1909-19.
12. Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J, Sevilla I, Escudero P, Sastre J, García-Donas J, Casanovas O, Earl J, Ortega L, Apellaniz-Ruiz M, Rodriguez-Antona C, Alonso-Gordoa T, Díez JJ, Carrato A, García-Carbonero R. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol. 2015 Sep;26(9):1987-93.
13. Garcia-Carbonero R*, Garcia-Figueiras R, Carmona-Bayonas A, Sevilla I, Teule A, Quindos M, Grande E, Capdevila J, Aller J, Arbizu J, Jimenez-Fonseca P; Spanish Cooperative Group of Neuroendocrine Tumors (GETNE). Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev. 2015 Dec;34(4):823-42.
14. Garcia-Carbonero R*, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C, Anlauf M, Cwikla J, Caplin M, O'Toole D, Perren A; all other Vienna Consensus Conference participants. ENETS Consensus Guidelines for High Grade Gastro-Entero-Pancreatic (GEP) Neuroendocrine Tumours and Neuroendocrine Carcinomas (NEC). Neuroendocrinology. 2016;103:186-194. (European guidelines)
15. Garcia-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Oncologist. 2017 Apr;22(4):375-e30.
16. Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors. Oncologist. 2017 Dec 14. pii: theoncologist.2017-0144. doi: 10.1634/theoncologist.2017-0144. [Epub ahead of print] PubMed PMID: 29242283.
17. Pavel ME, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony L, Kunz P, Hörsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, García-Carbonero R. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocr Relat Cancer. 2018 Mar;25(3):309-322.
18. Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M, Pi Barrio JJ, Teule A, Alonso V, Custodio A, Marazuela M, Segura Á, Beguiristain A, Llanos M, Martinez Del Prado MP, Diaz-Perez JA, Castellano D, Sevilla I, Lopez C, Alonso T, Garcia-Carbonero R*. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). Oncologist. 2018 Apr;23(4):422-432.